Article
Effectiveness and safety of sofosbuvir plus ribavirin for the treatment of HCV genotype 2 infection: results of the real-world, clinical practice HCV-TARGET study.
Gut - 1 Oct 2017
Welzel Tania M, Nelson David R, Morelli Giuseppe, Di Bisceglie Adrian, Reddy Rajender K, Kuo Alexander, Lim Joseph K, Darling Jama, Pockros Paul, Galati Joseph S, Frazier Lynn M, Alqahtani Saleh, Sulkowski Mark S, Vainorius Monika, Akushevich Lucy, Fried Michael W, Zeuzem Stefan
Abstract excerpt
OBJECTIVE: Due to a high efficacy in clinical trials, sofosbuvir (SOF) and ribavirin (RBV) for 12 or 16 weeks is recommended for treatment of patients with HCV genotype (GT) 2 infection. We investigated safety and effectiveness of these regimens for GT2 in HCV-TARGET participants. DESIGN: HCV-TARGET, an international, prospective observational study evaluates clinical practice data on novel antiviral therapies at...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.